[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"White River Junction Veterans Affairs Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,73,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100618794","transcranial-magnetic-stimulation-in-veterans-with-ptsd-100618794",false,"NCT07336251","Transcranial Magnetic Stimulation in Veterans With PTSD","Transcranial Magnetic Stimulation in Veterans With PTSD: A Pilot Study to Examine Mechanism of Effect","Inclusion Criteria:\n\n* Age between 19 and 70\n* Eligible for VA healthcare\n* Moderate to severe PTSD as determined by a total score of at least 25 on the CAPS within 7 days of randomization.\n* Agree to have CAPS audio recorded.\n* Ability to obtain a Motor Threshold using the TMS device during screening.\n* If female with childbearing potential, use of acceptable method of birth control (i.e., use of contraceptives, abstinence).\n* Able to read, understand, and sign the informed consent document.\n\nExclusion Criteria:\n\n* Pregnant or lactating woman.\n* MRI is contraindicated\n* Current use of clozapine (any dose) or bupropion (more than 300mg per day).\n* Cardiac pacemaker or implantable defibrillator.\n* Presence of any metal object in the head, including cochlear implants, but excluding dental work in the mouth.\n* Significant central nervous system disorder (stroke, brain mass, epilepsy).\n* Seizure in past one year.\n* Current psychosis or mania.\n* Significant suicidal ideation.\n* Unstable medical conditions.\n* Current alcohol or substance use disorder (except nicotine) that interferes with the patient's ability to participate.\n* CPT or PE for PTSD in the past 2 months.\n* Changes in Fluoxetine, Paroxetine, Sertraline, or Venlafaxine in the past 2 months.\n* Color blind\n* Currently participating in other research studies.\n* Aneurysm Clip\n* Ocular foreign body (e.g., metal shavings)\n* Any implanted device (pumps, infusion devices, etc.)\n* Shrapnel injuries or metal fragments","ALL","19 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","With this research investigators hope to begin to understand how rTMS can improve posttraumatic stress disorder (PTSD) symptoms. TMS improves PTSD through two interrelated mechanisms: change in brain limbic system function and change in systemic inflammatory activation. Participants who decide to join this study, will receive ten rTMS treatments. All participants will undergo a 40-minute rTMS procedure with a member of the study team 10 times over 2-4 weeks. Participants will undergo fMRI scans of the head in order to help researchers better understand potential effects of rTMS on brain activity. In addition, participants will be asked to give two breath and blood samples to look for signs of general inflammation.",[27],"PTSD - Post Traumatic Stress Disorder","RECRUITING","2026-06-11",{"date":31,"type":32},"2026-06-15","ACTUAL",{"date":34,"type":32},"2026-01-15",{"date":36,"type":21},"2027-01",{"name":38,"class":39},"White River Junction Veterans Affairs Medical Center","FED",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100500447","phase-2-replacing-invasive-cystoscopy-with-urine-testing-for-non-muscle-invasive-bladder-cancer-surveillance-100500447","NCT05796375","Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance","ReplaceCysto","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. History of low grade intermediate-risk non-muscle invasive bladder cancer, defined as most recent pathology report showing any of the following:\n\n   * multifocal low grade non-invasive urothelial carcinoma of any size\n   * solitary low grade non-invasive urothelial carcinoma greater than 3cm in size\n   * recurrent low grade non-invasive urothelial carcinoma\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. No evidence for recurrence at cystoscopy ≤6 months after most recent tumor resection\n5. Ability to consent in English or Spanish\n\nExclusion Criteria:\n\n1. History of total cystectomy of the bladder.\n2. History of urinary diversion (e.g., neo-bladder, colon pouch, or ileal conduit).\n3. History of muscle-invasive bladder tumor.\n4. Pregnancy or lactation.\n5. History of urothelial carcinoma of the ureter or renal pelvis status post endoscopic treatment or with evidence of recurrent upper tract disease (inclusion allowed if status post nephroureterectomy and recurrence free at time of inclusion)\n6. Anatomic constraints making cystoscopy impossible (e.g., history of urethrectomy, obliterated urethra secondary to stricture).\n7. Inability to provide a voided urine sample.","18 Years",{"count":50,"type":21},240,[52],"PHASE2","The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.",[55],"Non-muscle-invasive Bladder Cancer",[57,58,59,60,61,62,63],"Bladder","Cancer","Urology","Cystoscopy","Xpert","EpiCheck","Urine test","2026-05-01",{"date":66,"type":32},"2026-05-04",{"date":68,"type":32},"2023-11-17",{"date":70,"type":21},"2028-12-30",{"name":38,"class":39},9,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":40},"100488266","phase-2-glecaprevirpibrentasvir-for-post-traumatic-stress-disorder-100488266","NCT05637879","Glecaprevir\u002FPibrentasvir for Post-traumatic Stress Disorder","Randomized Controlled Trial of Glecaprevir\u002FPibrentasvir for the Treatment of Post-traumatic Stress Disorder","Inclusion Criteria:\n\n1. Age 19-70 years\n2. Weight ≥ 45 kg\n3. Diagnosed with PTSD as determined by the CAPS-5 within seven days of enrollment\n4. Eligible for Veterans Affairs healthcare\n5. If person with childbearing potential, use of acceptable method of birth control (i.e., effective contraceptives, abstinence) is required.\n6. Able to read, understand, and sign the informed consent document.\n\nExclusion (unable to participate) Criteria:\n\n1. Pregnant or lactating person\n2. Moderate or severe hepatic impairment (Child-Pugh B or C)\n3. History of prior hepatic decompensation\n4. Current use of drugs listed as having significant drug interactions on prescribing label\n5. Advanced liver disease\n6. Current or prior hepatitis B infection\n7. Prior clinical use of GLE\u002FPIB or HCV NS5A inhibitor AND NS3\u002F4A protease inhibitor\n8. Current HCV infection\n9. Current psychosis or mania\n10. Significant suicidal ideation\n11. Unstable medical conditions\n12. Current severe alcohol or substance use disorder (excluding nicotine)\n13. Evidence-based PTSD psychotherapy changes in the past two months\n14. Evidence-based PTSD medication changes in the past two months",{"count":81,"type":21},92,[52,83],"PHASE3","A double-blind randomized placebo-controlled trial to further investigate glecaprevir\u002Fpibrentasvir (GLE\u002FPIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).",[86],"PTSD",[86,88,89],"Antiviral","Hepatitis C","2025-04-18",{"date":92,"type":32},"2025-04-24",{"date":94,"type":32},"2023-12-18",{"date":96,"type":21},"2026-09-30",{"name":38,"class":39},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":106,"targetDuration":108,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100379463","endoscopic-resection-of-large-colorectal-polyps-an-observational-cohort-study-100379463","NCT04220905","Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort Study","Large Polyp Study (LPS) III - Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort Study","Inclusion Criteria:\n\n* Any patient ≥18 who presents for an upper endoscopy or colonoscopy and who does not have criteria for exclusion\n* Patients with a ≥20mm colon polyp\n* Patients with a ≥10mm duodenal polyp\n\nExclusion Criteria:\n\n* Patients who are receiving an emergency endoscopy\n* Patients with coagulopathy with an elevated INR ≥1.5, or platelets \\\u003C50\n* Poor bowel preparation\n* Pregnancy",true,{"count":107,"type":21},1500,"5 Years","OBSERVATIONAL","This protocol describes a prospective cohort study. It addresses an important challenge in the prevention of colorectal cancer and duodenal cancer: how to safely and effectively remove large polyps.",[112,113,114,115,116],"Colonic Polyp","Colonoscopy","Complication","Recurrence","Duodenal Polyp","2024-07-01",{"date":119,"type":32},"2024-07-05",{"date":121,"type":32},"2017-11-01",{"date":123,"type":21},"2025-05",{"name":38,"class":39},""]